Carbidopa API

Name	Carbidopa
Chinese name	卡比多巴
Cas Number	38821-49-7
Source	Europe
Qualifications	USDMF/CEP/-/-/-

Carbidopa is a dopa decarboxylase inhibitor developed by Merck, USA. Carbidopa cannot penetrate the blood-brain barrier and only inhibits the conversion of peripheral levodopa into dopamine, increasing the amount of levodopa entering the brain, and reducing the adverse reactions caused by peripheral dopamine, making levodopa in the circulation The content is increased; due to the increase of levodopa entering the brain, levodopa enters the brain center to transform into dopamine and play a role, which can improve the symptoms of paralysis. The combined use of carbidopa and levodopa has a synergistic effect. It has always been the first choice for the treatment of Parkinson's disease. It has a small dosage, mild adverse reactions and good curative effect. Levodopa/carbidopa can increase the patient's "on time", that is, the time period during which the drug is effective and the patient's symptoms are under control, without causing movement disorders, which can better control Parkinson's The patient’s motor symptoms time. In the four clinical trials, patients receiving levodopa/carbidopa treatment experienced a statistically significant reduction in the daily "off" period compared with the placebo group. In 2019, the global sales of L-Dopa/Carbidopa were RMB 3.175 billion.

Hot Tags: carbidopa api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Aprepitant Aprepitant API, Escitalopram Oxalate API, Lifitegrast API, Paliperidone API, Pazopanib Hydrochloride Pazopanib API, Gabapentin API

• Previous: Ramipril API
• Next: Dasatinib API